The pharmaceutical landscape has witnessed a groundbreaking shift with the emergence of copyright and Wegovy, two medications developed to address the complex issue of obesity. These advanced treatments leverage the potential of glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs known to regulate appetite and blood sugar levels. By